SEC Form 4 · accession 0001209191-18-019435
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas F Kearns Jr.
Director
Period of report
Mar 12, 2018
Accepted (ET)
Mar 13, 2018 · 8:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 6, 2018 | G | 500 | $0.00 | D | 135,064 | D | |
| Common Stock | Mar 12, 2018 | M | 18,000 | $3.60 | A | 153,064 | D | |
| Common StockF1 | Mar 12, 2018 | S | 18,000 | $55.00 | D | 135,064 | D | |
| Common Stock | holding | — | — | — | 110,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.60 | Mar 12, 2018 | M | 12,000 | D | — | Mar 11, 2019 | Common Stock | 12,000 | 0 | D |
| Stock Option (Right to Buy)F2 | $3.60 | Mar 12, 2018 | M | 6,000 | D | — | Mar 11, 2019 | Common Stock | 6,000 | 0 | D |
Explanation of responses
- F1The shares were sold at prices ranging from $54.70 to $55.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2Fully vested.